{"product_id":"mdwd-ansoff-analysis","title":"(MDWD) MediWound Ltd. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis MediWound Ltd. Ansoff Matrix Analysis outlines the company’s growth options across market penetration, market development, product development, and diversification—showing what MediWound’s products are, their uses, and strategic directions. This page includes a real preview\/sample of the analysis so you can evaluate style and substance before buying; purchase the full version to receive the complete ready-to-use report. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexoBrid adoption in specialized burn centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMediWound’s penetration play is deeper NexoBrid use in the burn centers already treating severe thermal burns. NexoBrid is a biological drug for enzymatic debridement of eschar in adults with deep partial- and full-thickness burns, so protocol adoption can raise share without a new sales footprint. The lever is frequency, not new accounts: more first-line use in existing centers means more cases per center.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital burn unit formulary depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNexoBrid already sits in hospital burn units, so deeper formulary placement is classic market penetration for MediWound Ltd. In 2024, the product’s value came from embedding it in debridement pathways, which can drive repeat use inside the same care setting instead of chasing new accounts. That makes each approved burn unit more valuable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult severe thermal burn focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNexoBrid is labeled for adults with severe thermal burns, so MediWound Ltd. can focus sales on the clearest need case and shorten account education. That tight indication helps defend share in burn centers, where adoption is driven by fast debridement and clinical fit.\u003c\/p\u003e\n\u003cp\u003eIn 2025, this kind of narrow market penetration matters more than broad reach: one approved use, one patient group, one repeatable hospital pathway. The smaller the indication, the easier it is to win and expand within current accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnzymatic eschar removal positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNexoBrid’s enzymatic debridement removes eschar without surgery, which is its clearest differentiator and a direct penetration play in existing burn-care markets. MediWound positions it against surgical and manual debridement, where centers are deciding how to treat compromised tissue in severe burns. As the only enzymatic eschar removal option, it targets a real workflow gap, not a new market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnly enzymatic eschar removal option\u003c\/li\u003e\n\u003cli\u003eCompetes inside current burn centers\u003c\/li\u003e\n\u003cli\u003eTargets severe-burn tissue decisions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBurn-care education and clinical uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurn-care education is key to MediWound Ltd.'s market penetration because adoption in current burn centers depends on clinician confidence, not just product access. In 2025, the company reported revenue of $17.8 million and continued U.S. commercialization of NexoBrid, which makes training on patient selection, timing, and severe-burn use central to repeat use.\u003c\/p\u003e\n\u003cp\u003eBetter clinical understanding can lift utilization in existing accounts, especially when teams see clearer fit in deep partial- and full-thickness burns. In a market where burn centers treat a small, specialized patient pool, even modest protocol uptake can matter, so education helps protect share and reduce trial-to-friction drop-off.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrain on patient selection\u003c\/li\u003e\n\u003cli\u003eTrain on timing of use\u003c\/li\u003e\n\u003cli\u003eTrain on severe-burn cases\u003c\/li\u003e\n\u003cli\u003eSupport sustained account use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMediWound’s growth hinges on deeper NexoBrid use in burn centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMediWound Ltd.’s market penetration is NexoBrid’s deeper use in existing burn centers, not new account growth. In 2025, revenue was $17.8 million, and the play is to raise repeat use in current U.S. burn units by embedding enzymatic debridement into standard severe-burn pathways.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$17.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore lever\u003c\/td\u003e\n\u003ctd\u003eMore use in current burn centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003eNexoBrid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget\u003c\/td\u003e\n\u003ctd\u003eDeep partial- and full-thickness burns\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps out MediWound Ltd.’s growth options across existing and new markets and products\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise MediWound Ltd. Ansoff Matrix analysis to quickly clarify growth options and reduce strategy planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources that validate MediWound Ltd. growth assumptions for Ansoff Matrix analysis, speeding due diligence and traceable verification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexoBrid geographic expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNexoBrid geographic expansion is MediWound Ltd.'s clearest market development move: it takes an approved burn debridement product into new countries and hospital systems without changing the core product. The FDA approved NexoBrid in December 2022 for adults and children age 4 and up, so each new territory can add specialized burn centers and widen access fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader hospital network access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNexoBrid can move from a few burn centers into more hospital burn pathways, widening access without changing the drug. That matters in a market where severe burns are concentrated but care is spread across hospital networks; each added site expands reach and referral flow. The upside is network scale, not a new product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReferral pathway expansion for severe burns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSevere thermal burns often start in local hospitals and move to burn centers through referral chains, so MediWound can widen NexoBrid access by adding more referring sites. That raises patient flow inside the same adult burn label and can lift treated volume without a new indication. In the U.S., about 29,000 burn injuries a year need hospital care, so referral reach matters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational commercialization of burn care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNexoBrid is MediWound Ltd.’s main tool for international market development, because the strategic goal is wider access to a burn-specific biologic, not a new product. The product is already cleared in the EU and the U.S., so expansion can focus on hospitals treating deep partial-thickness and full-thickness burns, a niche tied to a global burn burden of about 11 million cases a year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNexoBrid drives cross-border uptake.\u003c\/li\u003e\n\u003cli\u003eTargets severe burn centers.\u003c\/li\u003e\n\u003cli\u003eExpands access, not the product line.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospital procurement expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospital procurement is the gatekeeper here: each new burn center or hospital system that adds NexoBrid can widen MediWound Ltd.’s adult eschar-debridement reach without changing the product or indication. In 2025, the main growth lever is not new use, but more stocked purchasing systems, which can lift volume through institutional adoption and repeat orders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame product, more hospital systems\u003c\/li\u003e\n\u003cli\u003eAdult eschar debridement only\u003c\/li\u003e\n\u003cli\u003eGrowth depends on procurement wins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMediWound Expands NexoBrid Reach Across More Burn Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket development for MediWound Ltd. is NexoBrid’s push into more countries, burn centers, and hospital networks without changing the product. The U.S. approval in December 2022 covers adults and children age 4+, and the global burn burden is about 11 million cases a year, so each new procurement win can expand reach inside the same adult eschar-debridement market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. approval\u003c\/td\u003e\n\u003ctd\u003eDec 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAge label\u003c\/td\u003e\n\u003ctd\u003e4+ years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal burn cases\u003c\/td\u003e\n\u003ctd\u003eAbout 11 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. hospital burn injuries\u003c\/td\u003e\n\u003ctd\u003eAbout 29,000 a year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMediWound Ltd. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEscharEx Phase II completion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEscharEx’s Phase II completion is a clear product-development step for MediWound Ltd. It moves the company beyond acute burns and into chronic, hard-to-heal wounds, a much larger care area. As a new therapy in wound care, it fits the Ansoff Matrix’s product-development play by adding a fresh asset to the existing market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMW005 Phase I\/II progression\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMW005 is in Phase I\/II clinical studies for low-risk basal cell carcinoma, so MediWound Ltd. is building a second pipeline beyond burn debridement. This is new product development in Ansoff terms: a novel dermatology-oncology use case for an existing R\u0026amp;D platform. The move broadens addressable market beyond its core enzymatic wound care franchise and adds clinical optionality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic wound therapy pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMediWound Ltd.’s chronic wound therapy pipeline is a product development move: EscharEx targets wounds that do not heal with standard care, so it adds a new solution to an adjacent clinical need. EscharEx is in Phase 3 development for chronic wounds, which marks a clear step beyond the Company Name’s burn-care base. That shift can open a larger care setting without changing the core debridement platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDermatology oncology candidate building\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMW005 moves MediWound from wound healing into low-risk basal cell carcinoma, widening the product mix without leaving its biologic tissue-regeneration base. Basal cell carcinoma is the most common skin cancer, and BCC makes up about 80% of non-melanoma skin cancers, so the market is large. The shift is new on disease and setting, but still uses the same platform strength.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew indication, same biologic engine\u003c\/li\u003e\n\u003cli\u003eTargets a high-volume skin cancer\u003c\/li\u003e\n\u003cli\u003eSupports broader portfolio growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegenerative biologics platform extension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMediWound’s regenerative biologics platform already proved it can turn damaged tissue science into a commercial product through NexoBrid, which is approved in the US and EU. Product development here means extending the same enzymatic and biologic base into new clinical assets, like EscharEx for chronic wounds, so the company can grow beyond one product and one use case.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses one science base for multiple wound products\u003c\/li\u003e\n\u003cli\u003eNexoBrid proves platform-to-product conversion\u003c\/li\u003e\n\u003cli\u003eEscharEx extends reach into chronic wounds\u003c\/li\u003e\n\u003cli\u003eLower R and D risk than starting from zero\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMediWound Expands Its Core Platform Into New Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMediWound Ltd. is using product development to extend one core biologic platform into new uses. EscharEx reached Phase II in chronic wounds, and MW005 is in Phase I\/II for low-risk basal cell carcinoma, adding a second disease area. NexoBrid, approved in the US and EU, shows the platform can convert into products.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEscharEx\u003c\/td\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003ctd\u003eChronic wounds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMW005\u003c\/td\u003e\n\u003ctd\u003ePhase I\/II\u003c\/td\u003e\n\u003ctd\u003eLow-risk BCC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexoBrid\u003c\/td\u003e\n\u003ctd\u003eApproved\u003c\/td\u003e\n\u003ctd\u003eCore platform proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic wound care entry with EscharEx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEscharEx moves MediWound Ltd. into chronic wound care, a market separate from acute thermal burns, so this is diversification: a new product in a new market. Chronic wounds affect about 6.5 million U.S. patients and can drive more than $28 billion in annual care costs, which shows the size of the opportunity. It also broadens MediWound Ltd. beyond its burn-focused base, adding a second growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-risk basal cell carcinoma entry with MW005\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMW005 is a low-risk basal cell carcinoma program that moves MediWound Ltd. into dermatology oncology with a new investigational product. That is a different market from burn-center debridement, so it lowers concentration risk and widens the addressable patient base beyond wound healing. Basal cell carcinoma is the most common skin cancer, with millions of cases diagnosed each year, which gives this diversification a much larger opportunity set.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-burn tissue repair markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMediWound Ltd. is moving from burn care into non-burn tissue repair, using the same enzymatic healing base behind NexoBrid, which is approved in 40+ countries for severe burns. Its EscharEx program targets chronic wounds such as venous leg ulcers and diabetic foot ulcers, a U.S. market tied to about 8 million chronic wound patients. That mix of new products and new demand spaces is clear diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospital and specialist clinic expansion beyond burns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurn care is MediWound Ltd.’s base, but EscharEx and MW005 push into chronic wounds and basal cell carcinoma, where care is led by different specialists and follows different patient paths. That makes this a diversification move, not just line extension. It can widen the addressable market beyond burn centers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEscharEx targets chronic wound clinics\u003c\/li\u003e\n\u003cli\u003eMW005 targets basal cell carcinoma care\u003c\/li\u003e\n\u003cli\u003eDifferent doctors, referrals, and workflows\u003c\/li\u003e\n\u003cli\u003eBroader reach than burn-only channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-indication biologic portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMediWound Ltd. is no longer tied to one burn product. Its portfolio now spans NexoBrid in burns, EscharEx in chronic wounds, and MW005 in low-risk basal cell carcinoma, so the clearest Ansoff move is diversification across three distinct indications.\u003c\/p\u003e\n\u003cp\u003eThis reduces single-asset risk and widens the addressable market. EscharEx is in Phase 3 for venous leg ulcers and diabetic foot ulcers, while MW005 extends the platform into dermatology, giving MediWound three shots at revenue from different clinical paths.\u003c\/p\u003e\n\u003cp\u003eThat mix matters because burns, chronic wounds, and skin cancer have different demand drivers, payers, and adoption curves. In simple terms: one platform, three markets, less dependence on any single product cycle.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThree indications: burns, wounds, skin cancer\u003c\/li\u003e\n\u003cli\u003eEscharEx: Phase 3 chronic wounds\u003c\/li\u003e\n\u003cli\u003eMW005: low-risk basal cell carcinoma\u003c\/li\u003e\n\u003cli\u003eBest-fit Ansoff path: diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMediWound’s Diversification Push Targets New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification is MediWound Ltd.’s clearest Ansoff move: it is pushing from burns into chronic wounds and dermatology oncology. EscharEx targets about 6.5 million U.S. chronic wound patients, and MW005 opens a second non-burn market, lowering reliance on one product and one care path.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eAnsoff fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEscharEx\u003c\/td\u003e\n\u003ctd\u003eChronic wounds\u003c\/td\u003e\n\u003ctd\u003eDiversification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMW005\u003c\/td\u003e\n\u003ctd\u003eBasal cell carcinoma\u003c\/td\u003e\n\u003ctd\u003eDiversification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234637259017,"sku":"mdwd-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mdwd-ansoff-matrix.webp?v=1785724837","url":"https:\/\/dcfanalyst.com\/products\/mdwd-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}